This qualitative case study (n=10) explored the experiences of opioid-dependent people in New Zealand who used ibogaine for detoxification. Participants described rapid withdrawal relief, better mood and less anxiety, and some sustained abstinence, but relapse still occurred and preparation, medical screening and post-treatment support were seen as important.
Opioid dependence is a public health concern in New Zealand, with limited treatment options beyond opioid substitution therapy (OST). Ibogaine, a psychoactive alkaloid with reported anti-withdrawal and anti-craving effects for opioid dependence, is legally available by prescription in New Zealand, offering a context for exploring user experiences. A qualitative collective case study design was used to examine the experiences and motivations of 10 opioid-dependent individuals who used ibogaine for opioid detoxification. Participants were recruited through ibogaine networks, OST services, and snowball sampling. Semi-structured interviews were conducted and analyzed using an inductive thematic analysis approach, informed by an interpretive, experiential framework. Analysis focused on how participants understood their motivations, treatment processes, safety practices, and post-treatment outcomes. Seven themes were identified: “Desperation to be opioid free,” “motivations for using ibogaine,” “safety conscious and support seeking,” “improving ibogaine practices,” “effects of treatment on depression and anxiety,” “effects of treatment on dependence,” and “the spiritual effect.” Participants associated ibogaine treatment with rapid detoxification, improved mood, reduced anxiety, and periods of sustained abstinence, though relapse occurred in some cases. Preparation, medical screening, and post-treatment psychosocial support were critical to positive outcomes. This study adds to the literature by documenting experiences of ibogaine use, with implications for clinical practice, policy, and future research.
Papers cited by this study that are also in Blossom
Köck, P., Frölich, K., Walter, M. et al. · Journal of Substance Abuse Treatment (2022)
Frampton, C. M., Yazar-Klosinski, B., Nollar, G. E. · The American Journal of Drug and Alcohol Abuse (2017)
Ona, G., Rocha, J. M., Bouso, J. C. et al. · Psychopharmacology (2021)
Alper, K. · The Alkaloids Chemistry and Biology (2001)
Opioid dependence is described as a persistent public health problem in New Zealand, with limited treatment options beyond opioid substitution therapy (OST). The paper notes that although methadone and related treatments have improved retention and health outcomes, some service users report physical discomfort, lower life satisfaction, and difficulties that may be related to treatment restrictions, wider lifestyle factors, or the medication itself. Against this backdrop, ibogaine is presented as a legally available but unapproved medicine in New Zealand that has been associated in earlier research with reduced withdrawal, cravings, and, in some accounts, spiritual or psychological change. At the same time, the paper emphasises that evidence remains limited and that serious cardiovascular risks have been reported, including QT interval prolongation, arrhythmias, and sudden cardiac death. The study set out to explore the lived experiences and practices of opioid-dependent people who used ibogaine for detoxification. The authors were particularly interested in motivations for treatment, understanding of health risks, use of pre-treatment medical screening, and the effects of ibogaine on later opioid use. They also aimed to use New Zealand’s legal prescribing context to better understand ibogaine use in a setting where users could discuss treatment more openly and receive medical input, rather than relying solely on clandestine or unregulated use.
Walker and colleagues used a qualitative collective case study design to examine the experiences of 10 opioid-dependent people in New Zealand who had used ibogaine specifically to treat their dependence. Ethics approval was obtained from the University of Otago Human Ethics Committee. Participants were screened for mental health diagnoses other than opioid use disorder during recruitment, and none were excluded on that basis. Participants were recruited through ibogaine networks, a Christchurch OST service, and snowball sampling. The sample included people aged 27 to 53 years, with ages at ibogaine treatment ranging from 21 to 49 years. The extracted text states that the sample was evenly split by gender and that all respondents identified as New Zealand European; it also notes that nine had histories of illicit opioid use and one had problematic opioid use related to chronic pain. Eight were on OST at the time of ibogaine treatment, and one had never used OST. Two participants received treatment overseas, while the rest were treated in New Zealand. Semi-structured interviews were conducted in locations chosen by participants, such as homes, cafés, and libraries. Interviews lasted about 45 to 90 minutes, were audio-recorded with consent, and transcribed verbatim. After each interview, participants completed a short questionnaire to capture demographic information, opioid use history, duration of dependence, prior treatment history, and opioid use after treatment. Participants received a $20 petrol voucher. The researchers analysed the transcripts using inductive thematic analysis. They generated 22 initial codes and then clustered these into seven higher-order themes through an iterative, interpretive process. The first author led coding and theme development, and discussion with two academic supervisors, an audit trail, and use of illustrative quotations were used to support rigour and credibility.
The 10 interviews produced seven themes: desperation to be opioid free; motivations for using ibogaine; safety conscious and support seeking; improving ibogaine practices; effects of treatment on depression and anxiety; effects of treatment on dependence; and the spiritual effect. Overall, participants’ accounts suggested that ibogaine was experienced not only as a detoxification aid but also as something that could influence mood, meaning-making, and later recovery trajectories. A strong desire to escape opioid use, including methadone, was a major driver. Participants described negative effects on mood, anxiety, and physical wellbeing, together with repeated unsuccessful detoxification attempts. Many were motivated by the hope that ibogaine would provide faster and more durable detoxification than conventional treatment, with less time away from work and family. Several had prior experience with hallucinogens or cannabis, and four explicitly sought spiritual healing or a deeper psychological change. The most persuasive motivator for some was seeing a peer who had used ibogaine and appeared markedly improved. Safety-related behaviour was prominent. All 10 participants sought medical testing from a general practitioner before treatment, and those working with an ibogaine provider generally completed the provider’s recommended screening and follow-up processes. Participants without a provider sometimes underwent tests that were less relevant to ibogaine safety. Half of the sample reported needing ongoing information, support, and in some cases booster doses after treatment. Participants also described what they saw as better practice, including the use of therapeutic dosing, hydration, sleep support, nausea management, and, for some, switching from longer-acting opioids such as methadone to shorter-acting opioids before treatment. They noted that vomiting or low dosing sometimes reduced the psychedelic effect or made the dose uncertain. Many still valued the hallucinogenic experience. Mood and anxiety improvements were reported very consistently. Participants said ibogaine reduced depression and anxiety, sometimes even at low doses, and that these benefits could persist for one to six months. Seven out of 10 reported remaining opioid-free, and five of these seven also reported abstinence from other substances. Three participants relapsed between three and six months after treatment. Two participants used booster doses around three months later for pain management with good effect. Some participants described spiritual or visionary experiences, including encounters with an African shaman-like figure, while others did not achieve the spiritual effect they had hoped for yet still obtained opioid abstinence.
The authors interpret the findings as showing that ibogaine experiences were shaped by an interplay of desperation, motivation, safety practices, treatment preparation, mood change, and spiritual meaning. They argue that dissatisfaction with OST, especially its unwanted mental and physical effects, increased hopes for ibogaine as a faster detoxification pathway. They also suggest that the reported benefits were not limited to withdrawal suppression but extended to improvements in anxiety and mood, sometimes described by participants as a psychological reset lasting weeks or months. Walker and colleagues position their findings as consistent with earlier research noting limitations of OST and the potential appeal of psychedelic or spiritually meaningful treatments. They also point out that booster doses, though mentioned in guidance, have limited evidence behind them. In their account, participants who used experienced providers, underwent recommended screening, and accessed post-treatment support tended to report smoother detoxification, fewer complications, and more sustained abstinence. By contrast, independent use without provider guidance was associated with less relevant screening and weaker follow-up, which the authors suggest may increase safety risks and reduce effectiveness. The authors highlight several limitations. The sample was small and hard to recruit, which constrained diversity and means the findings cannot be generalised to all ibogaine users. Participants were all New Zealand European, limiting wider inference. All outcome data were based on retrospective self-report, so recall bias, selective reporting, and unverified claims about abstinence, relapse, withdrawal, and mood changes are possible. The authors also note that theoretical saturation was not formally assessed, although later interviews reportedly continued to reinforce the same themes. In terms of implications, the authors argue that future ibogaine provision in New Zealand should prioritise professional oversight, comprehensive medical screening, symptom management, and sustained psychosocial support. They suggest that the legal prescribing context may have allowed more open discussion with general practitioners and better access to care. They also note that low-dose booster treatments were valued by participants, but formal prescribing guidance remains absent. More broadly, they present the study as adding context-specific evidence that may inform clinical practice, policy, and future research on safer ibogaine use.
The authors conclude that participant experiences ranged from highly supported treatment under a specialised ibogaine provider to more independent use with less appropriate screening and follow-up. They state that preparation, planning, and recovery time were central to whether ibogaine was experienced positively and whether opioid abstinence was achieved. The study is presented as offering novel insight from a legal prescribing environment, and the authors conclude that ibogaine may have potential as a detoxification tool when paired with professional oversight, medical screening, symptom management, psychosocial support, and, where appropriate, booster dosing.
The study aimed to explore the experiences and practices of opioid-dependent individuals who had used ibogaine as an intervention for opioid dependence, focusing on motivations for treatment, understanding of health risks, use of pre-treatment health tests, and effects on subsequent opioid use. A collective case study methodology) was employed to capture both individual decision-making processes and shared themes across cases. This approach was selected for its suitability in examining the complex interplay of physiological, psychological, social, and political factors influencing treatment choices in addiction medicine, where qualitative case studies have been effectively applied. Interviews were chosen for their capacity to elicit nuanced insights.
Ethics approval (H15/042) was granted by the University of Otago Human Ethics Committee. Participants were screened for mental health diagnoses (excluding opioid use disorder) as an exclusionary criterion during the recruitment phase of the study. No participants were excluded due to their mental health status. The study sample comprised 10 New Zealanders who were currently or previously opioid dependent and had used ibogaine specifically to treat their dependence. Descriptions of participants opioid use history is provided in Table. Participants were aged 27 to 53 years (M = 40.2), with ages at ibogaine treatment ranging from 21 to 49 years (M = 35.1). All respondents identified as New Zealand European. Participants were recruited via informants at the Iboga Association Aotearoa (n = 8), a Christchurch OST service (n = 1), and snowball sampling (n = 1). Two respondents had received treatment overseas, the rest had experiences within New Zealand. The sample was evenly split by gender; nine reported illicit opioid use histories, while one reported problematic opioid use related to chronic pain management. Eight participants were on OST at the time of ibogaine treatment, and one had never used OST. All respondents identified as New Zealand European, and other ethnic groups were not represented.
Interviews were arranged at locations chosen by participants, including private homes, public cafés, and local libraries. Prior to commencement, participants were provided with an information sheet outlining the study's purpose, procedures, and participant-related rights. Written informed consent was then obtained. A semi-structured interview guide was used to ensure consistency while allowing flexibility for participants to elaborate on personal experiences. Key topics explored were: (1) motivations for choosing ibogaine; (2) understanding of treatment risks; (3) completion of any pre-treatment health checks; (4) the treatment setting and environment; and (5) the effects of ibogaine on subsequent opioid use. Interviews typically lasted between 45 and 90 minutes and were audio-recorded with consent. Recordings were transcribed verbatim by the researcher, and transcripts were checked for accuracy against the original audio. Following the interview, participants completed a brief questionnaire adapted fromto collect standardized demographic information (age group, gender, ethnicity), opioid use history, duration of dependence before ibogaine treatment, prior treatment history, and opioid use patterns following treatment. Participants were provided with a $20 petrol voucher as a token of appreciation for their time and travel.
All interview transcripts and case descriptions were read repeatedly for familiarization, and an inductive thematic analysis was conducted. A total of 22 initial codes were generated to capture distinct areas of focus raised by participants. Each code was subjected to a process of systematic review, where overlaps and connections were identified, and broader patterns began to emerge. Codes were inductively developed and iteratively clustered into higher-order themes based on conceptual similarity and analytic relevance, rather than organized into a formal hierarchical structure. This approach reflects the interpretive and non-linear nature of the thematic analysis undertaken. Through this iterative process, the 22 codes were distilled into seven overarching themes that represented the most salient and recurrent patterns across the dataset. Codes reflecting discomfort and ambivalence with opioid use were grouped under "desperation to be opioid free." Motivations for ibogaine treatment, such as dissatisfaction with conventional care or desire for abstinence, formed "motivations for using ibogaine." Safety-related codes, including personal precautions and support-seeking, were integrated into "safety conscious and support seeking." Reflections on care standards informed "improving ibogaine practices." Emotional outcomes such as reduced anxiety and improved mood shaped "effects of treatment on depression and anxiety," while changes in substance use patterns informed "ibogaine treatment effects on abstinence." Finally, transcendental or existential experiences were synthesized into "the spiritual effect." Together, these themes provided a structured framework for understanding the ways in which participants conceptualized and made meaning of their ibogaine treatment experiences, moving from discrete coded observations to broader interpretive insights. Coding and theme development were undertaken by the first author, a New Zealand European with a biomedical and clinical background in addiction services, who maintained reflexive awareness of positionality. To enhance credibility and reduce interpretive bias, coding decisions and thematic development were discussed with two academic supervisors who provided ongoing feedback. An audit trail of coding decisions was maintained, and illustrative quotes were used to support each theme, providing transparency and ensuring that findings remained grounded in participants' accounts. This thematic analysis approach is well established as an effective method for interpreting verbal interview data. Prior to analysis, specific analytic strategies were selected in line with
The analysis of 10 recorded and transcribed interviews with individuals who had used ibogaine for opioid dependence revealed both deeply personal narratives and a shared, collective experience. While each participant's journey reflected unique circumstances, motivations, and challenges, there were notable patterns across accounts. These patterns coalesced into seven overarching themes that capture the core aspects of participants' experiences. Together, these themes offer insight into how ibogaine treatment was understood, experienced, and integrated into participants' lives.
This group of respondents reported a desire to be free of opioid use, including no longer using substitution opioids. It was described as no longer wanting the effects of the narcotic in their body and mind. Negative effects on mood was voiced as the strongest motivator, followed by effects on the physical body. This was described when using illicit opioids and substitution opioids, mostly methadone. Daily anxiety was reported by half the respondents, attributed to the effects of opioids. 004 These effects caused some to keep substitution doses at a sub-therapeutic level. The group had an anti-establishment view of standard addiction treatments, but most utilized methadone (OST) treatment. This group reported severe low moods associated with opioid withdrawal. Most respondents reported multiple desperate, unsuccessful attempts at opioid detoxification. Prolonged withdrawal symptoms, depression, and "an anxiety" about life without drugs were key contributing relapse factors.
Respondents described a sense of hope that this form of treatment would have long-term success and alleviate opioid withdrawal during the detoxification stage. The reported quickness of treatment time with ibogaine was also described as attractive, reducing an expected sixmonth recovery time to sometimes less than two weeks. 004: . . . I had asked about going to a rehab center or something like that. Everything took so long, and I had my own business and family, like how could I take six months out. The legality of ibogaine treatment did not influence respondents' decision to use it, but it did affect the level of medical input they received during treatment. Many participants reported prior positive experiences with recreational hallucinogens such as LSD and psilocybin mushrooms, and most described a strong relationship with cannabis use. This attraction to what they termed "psycho-stimulating drugs" appeared to be part of their motivation for selecting ibogaine. Four respondents specifically sought spiritual healing or a profound psychological resolution they believed would support sustained abstinence from opioids, and considered ibogaine treatment as a potential means to achieve this. The most frequently cited motivator, however, was knowing someone who had been opioid dependent, undergone ibogaine treatment, and demonstrated changes the respondents themselves wished to experience. 009: And then I saw him two years later . . . and he turned up here to tell A. and I his experience with the ibogaine. And it was like he had gone . . . like the last time I saw him, he was 10 years older than he was. And now he had "Peter Panned" it totally and looked like he was 10 years younger than he was.
All 10 respondents sought medical testing from their general practitioner (GP) before ibogaine treatment, even the independent user of ibogaine. 002: . . . and I think other stuff I read, because it was people that had a weak heart. So to get a medical for something illegal, you needed to see your doctor and then go through the medical fraternity, so shit, alright, it was going to come out what you're doing. Respondents who engaged with an ibogaine treatment provider reported completing the recommended pre-treatment medical tests and screenings, as guided by their provider. In these cases, providers supplied a list of required assessments, which were completed before treatment could proceed. By contrast, respondents who did not work with a treatment provider reported obtaining pre-treatment tests that were not recommended and potentially irrelevant. Following the legal availability of ibogaine as an off-license medicine in New Zealand, participants described having access to medical support during and after treatment, including nausea management and sleep augmentation. Half the respondents indicated that they required ongoing information, support, and, in some cases, booster doses of ibogaine from their treatment providers.
The theme of improving ibogaine practices emerged when respondents described variations in ibogaine treatments and what they would have done differently. This includes utilizing a therapeutic dose of ibogaine and being able to use booster doses during treatment and months afterward. 003: yup um. and then they gave me a booster at that point of time. About 200mgs. I didn't want to take it, I was like what is that shit you gave me, its hard core! But I thought "I trust these girls." Participants also described pragmatic strategies to support ibogaine treatment, such as maintaining hydration and managing sleep disturbances and nausea. It was emphasized that transitioning to shorter-acting opioids (with a shorter drug half-life) prior to ibogaine treatment was more effective for managing withdrawal symptoms than detoxifying from longer-acting opioids such as methadone. Most respondents sought a hallucinogenic effect from the treatment, although this was sometimes diminished by low dosing of ibogaine or by vomiting occurring during the ingestion of ibogaine that resulted in an unknown dosage.
This theme reflects respondents' accounts of ibogaine's capacity to improve mood and reduce anxiety, even at low doses. Participants strongly emphasized this effect as the primary reason they did not feel the need to use other drugs or return to opioid use. The improvement in mood was frequently described alongside feelings of reduced anxiety, and in some cases, a complete absence of anxiety. 002:That anxiety wasn't there! Oh, it was like you might have fleeting thoughts, but they were just like fleeting, and there wasn't that . . . upwelling of; "Oh, I got to go and score." And that got me through to the six-month period, and I've just really never looked back. It's just been that was it. You know. Respondents attributed these improvements not only to the removal of opioids from the body but also to the hallucinogenic effects of ibogaine itself. The enhanced mood and reduced anxiety were reported to persist for one to six months following treatment. During this same period, participants described experiencing little or no opioid withdrawal symptoms, which they felt further contributed to reduced anxiety and improved mood.
Seven out of ten respondents reported remaining opioid-free, and five of these seven also reported abstinence from other substances. Three respondents experienced opioid drug relapse between three and six months following their ibogaine treatment. Across the sample, ibogaine was described as effectively eliminating opioid withdrawal symptoms during the detoxification phase and as improving mood and reducing anxiety in the recovery period after treatment. 005: So the first two weeks, there was no craving for absolutely anything. No alcohol, no benzos, no ciggys even. But then after about two weeks, the first craving that came to me was for ciggys, and that was after about two weeks um . . . and um . . . I hadn't . . . I think I went close to a month before I had a beer . . . Yeah, I guess the interesting thing about that is that I had um . . . one beer and I felt like I was tripping again. Two respondents used booster doses of ibogaine three months after initial treatment for management of pain with good effect. 004: OK, three months . . . was the first time I had this sort of doubt about future thinking, like, what am I going to do now? You know, how do I face this pain without medication? Yeah, the end of the bubble basically. And so . . . I took, like, a top up dose . . .Theme 7: the spiritual effect A recurring motivation identified by respondents for using ibogaine was described as the "spiritual effect." Several participants reported that the impact of ibogaine extended beyond mental and emotional changes to encompass a sense of spiritual transformation. Some respondents described their experience as negative due to not attaining the spiritual effect they had hoped for, but they still achieved opioid abstinence. Two respondents characterized opioids themselves as a "block" to personal spirituality. This theme includes accounts from the same two individuals who reported experiencing spiritual-like epiphanies during the active phase of ibogaine treatment, including visions of being visited by an African shaman. These experiences were later associated with physical and emotional healing, as well as the removal of "all" anxiety. 004: So I have this African dude in front of me, and he is talking to me in this kind of pigeon garbled English type of thing . . . "Oh bugger, we will have to use the cellshaking method" . . . And I was sitting there going, what the fuck is the cell-shaking method, and how is that going to work?
This study explored the lived experiences and motivations of opioid-dependent individuals in New Zealand who undertook ibogaine treatment for detoxification. The findings suggest that participants' outcomes, ranging from sustained abstinence to relapse, were shaped by a complex interplay of the key themes highlighted: "desperation to be opioid free," "motivations for using ibogaine," "safety conscious and support seeking," "improving ibogaine practices," "effects of treatment on depression and anxiety," "the effects of treatment on dependence," and "the spiritual effect." The unwanted mental and physical effects of OST increased participants' hopes for ibogaine treatment, which was inspired by online reports of rapid detoxification with fewer symptoms. This aligns with De Maeyer et al. (2011) and, who noted OST's adverse physical and mental side effects. Booster doses given 2-4 days post-treatment further reduced withdrawal symptoms; some used boosters months later for pain management. Though booster usage is suggested in guidelines, literature on its efficacy remains limited. A central observation is the influence of preparation and planning. Participants who engaged with experienced ibogaine providers, completed recommended pre-treatment medical screening, and accessed posttreatment support generally reported smoother detoxification, fewer complications, and more sustained abstinence. This highlights the importance of comprehensive screening and aftercare in reducing risks associated with ibogaine use. Such tests appeared to be more available when access to Ibogaine was legal. In contrast, independent use without provider guidance often led to less relevant screening and limited follow-up, potentially increasing safety risks and reducing treatment efficacy. Ibogaine's reported effects extended beyond withdrawal suppression to include improvements in mood and anxiety, with several participants describing a "reset" that persisted for weeks or months. The "spiritual effect" was valued by some participants as integral to their recovery, reinforcing literature on the therapeutic role of meaning-making in psychedelic treatments. However, not all experiences were uniformly positive. Three participants relapsed within six months, often coinciding with declines in mood after the initial posttreatment "bubble" subsided. This underscores the need for structured psychological and social support during recovery. The experience of ibogaine users in New Zealand is summarized in Figure.
Recruitment for this study presented significant challenges due to the niche and often private nature of the ibogaine-using population in New Zealand. Although the sample size of 10 participants may be considered small, it reflects the realities of accessing a hard-to-reach group who have undergone treatment. Participants were primarily recruited through trusted informants and snowball sampling, methods necessary to build rapport and trust within this community, which may limit sample diversity. Interviews were conducted in various locations to help further facilitate engagement with this population; however, this variability may have influenced participant disclosure. Future research could address these recruitment limitations by employing broader, multi-site collaboration and integrating mixed-method approaches to reach a wider and more representative sample of ibogaine users. This would enhance generalizability and deepen understanding of varied user experiences. Studies such as the current research can also help to serve as rapport builders within these communities. All outcome data, including reports of abstinence, relapse, withdrawal symptoms, and mood changes, were obtained entirely through participants' retrospective self-reports. These accounts could not be independently verified through objective measures such as toxicology screening, medical records, or collateral informants. As such, the accuracy of reported experiences and timelines is reliant on participant recall and willingness to disclose, introducing the potential for recall bias, selective reporting, or omission of adverse outcomes. The nature of case study research, even from a single case study, can illuminate reasons and answers for complex social and personal actions of individuals. Historically, such answers have guided broader application of findings, such as case study research demonstrating early the benefits of methadone treatment leading to initial public clinics in the United States). However, the data cannot ever be generalized for the whole population. The small sample size (10) in this study and no ethnic diversity (primarily White in a Westernized nation) in the respondents also limit any inferences to wider populations. Furthermore, due to the stated recruitment challenges limiting the sample size, theoretical saturation was not formally assessed; however, the consistent repetition of themes and absence of new information in later interviews suggest that key constructs were adequately captured.
The findings highlight several considerations for enhancing ibogaine treatment and broader opioid dependence management in New Zealand. Experienced ibogaine providers were associated with safer and more effective outcomes, particularly when comprehensive pre-treatment medical screening and sustained post-treatment support were offered. This education and support role will be crucial for future ibogaine service provision in New Zealand, especially as participants reported greater openness with GPs and access to care when ibogaine was legally prescribed, supporting current legislation that allows ibogaine as an off-label registered medicine for opioid detoxification. Respondents also valued the hallucinogenic aspects of ibogaine, which they perceived as beneficial for mood and anxiety management, aligning with literature on hallucinogenic treatments for psychiatric disorders such as depression. Finally, the use of low-dose "booster" ibogaine treatments (200-400 mg) after initial detoxification was reported to reduce withdrawal and pain symptoms without further psychedelic effects, although formal prescribing guidelines for boosters remain absent.
Participant interviews revealed distinct experiences of ibogaine treatment, ranging from those who engaged a specialized ibogaine treatment provider, followed recommended pre-treatment medical screening, and accessed appropriate medical support, to a minority who obtained ibogaine independently, consulted only their general practitioner, and underwent non-recommended screening tests. Positive treatment experiences and the attainment of the desired outcome, opioid abstinence, appeared to be strongly influenced by the individual's preparation and planning, both before and after treatment. All participants, including the three who relapsed, emphasized the importance of planning, particularly recovery time. Having an ibogaine treatment provider was associated with greater access to appropriate medical care and post-treatment support. The study adds novel insight by documenting key themes in ibogaine use within a legal prescribing environmental context that enabled open discussion with healthcare providers and access to appropriate medical care. This setting differs markedly from the clandestine or unregulated contexts in which ibogaine is typically administered internationally. While findings support ibogaine's potential as a tool for opioid detoxification, they also highlight essential conditions for safer, more effective use being professional oversight, medical screening, symptom management, psychosocial support, and, where appropriate, booster dosing.
No potential conflict of interest was reported by the author(s).
Create a free account to open full-text PDFs.
Strassman, R. J. · Journal of Nervous and Mental Disease (1995)